Circulating Tumor Cells can be found in the blood of patients with primary tumor. These cells are extraordinarily rare and their detection presents a major challenge. But collaboration between bioengineers, molecular biologists and clinicians, many technologies have been developed which can detect CTCs. There are many ongoing research on this which are facilitated by the reports generated earlier. Because of the circulating tumor cells clinical significance, there has been a lot of stress on developing methods that can allow detailed studies across multiple types of cancer and its detection.
Detailed study on CTC technologies shows that this field of biotechnology can offer unique opportunities for the detection of tumor cells in patients with early stage cancer. It also confirms the ability to genetically characterize tumor cells without needing an invasive biopsy, and determine responsiveness to the new generation targeted cancer drugs. Some of the latest reports even discuss the ability of CTC technology to offer the opportunity to study “cancer stem cells” or “metastasis precursors” which were thought to be at the origin of cancer spread via the bloodstream, to define their molecular vulnerabilities and help design new therapies to prevent cancer metastasis.
Clinical research on circulating tumor cells technologies can be considered to be in its early stages and it has a long way to go. This field of research work is getting mass support from private and government organizations and reaching new heights every day. Its remarkable significance in pharmaceutical industry is encouraging many investors and business person to invest in its R&D for discovery of some technologies that really bring some highly effective difference in the process of cancer detection. Hope of a number of cancer institutions and future of cancer patients depend on the development of CTC technologies. The next generation of clinical trials is waiting to be designed based on the upcoming reports.
RI Technologies develops reports on circulating tumor cells technologies which can prove to be a great aid for future R&D. It provides a complete market insight into technologies and services used for cancer detection and serves as a guide to CTC industry. Profiles of more than 150 companies are discussed who are engaged in CTC studies, screening, products or services. Clients can get information related to recent product releases, development, partnerships, collaborations, and mergers and plan their business strategies for smooth market entry. A complete report on future of CTC industry, its estimations and predictions are presented which are relevant to client’s requirements. For more information ask for some sample pages. Visit